1. Home
  2. XPON vs REVB Comparison

XPON vs REVB Comparison

Compare XPON & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expion360 Inc.

XPON

Expion360 Inc.

HOLD

Current Price

$0.67

Market Cap

6.2M

Sector

Technology

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.79

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPON
REVB
Founded
2016
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
XPON
REVB
Price
$0.67
$0.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
235.3K
113.7K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,417,947.00
N/A
Revenue This Year
$61.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
109.37
N/A
52 Week Low
$0.60
$0.76
52 Week High
$5.50
$60.48

Technical Indicators

Market Signals
Indicator
XPON
REVB
Relative Strength Index (RSI) 24.14 31.56
Support Level $0.83 $0.85
Resistance Level $1.26 $0.90
Average True Range (ATR) 0.08 0.07
MACD -0.02 -0.01
Stochastic Oscillator 2.06 6.25

Price Performance

Historical Comparison
XPON
REVB

About XPON Expion360 Inc.

Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: